Match Document Document Title
6891024 Monoclonal antibodies to Sarcocystis neurona and uses therefor  
The present invention is directed to particular monoclonal antibodies that find use in the identification and purification of Sarcocystis neurona and related antigens. In particular, these...
6887481 Bacterial-derived molecules and therapeutic and diagnostic uses therefor  
The present invention relates generally to molecules derived from a Mycobacterium species and recombinant, synthetic, derivative, homologue and analogue forms of said molecules. The molecules of...
6887473 Inhibition of angiogenesis in disease states with an anti-αvβ3 monoclonal antibody  
The present invention describes methods for inhibition angiogenesis in tissues using vitronectin α v β 3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in...
6884418 Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy  
This invention is directed toward novel synergistic combinations of ligand-mimicking agents specific to the c-erbB-2 protein and anti-neoplastic drugs or agents, which can be used to treat a...
6881405 Reagents and methods for inducing an immune response to prostate specific antigen  
The invention is an apparatus and method for the treatment of prostate cancer, and involves administering an antibody that specifically binds with prostate antigen.
6881407 Method for treating hepatitis  
Hepatitis can be treated by administering to a patient in need thereof an effective amount of a compound that neutralizes the effects of secreted TNFalpha. Two types of these compounds are...
6881406 Modulation of systemic memory T cell trafficking  
Methods are provided to specifically modulate the trafficking of systemic memory T cells, particularly CD4+ T cells, without affecting naive T cells or intestinal memory T cells. It is shown that...
6875432 Reduced-viscosity concentrated protein formulations  
The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method...
6872392 Humanized antibodies  
Chimeric human antibody expression vectors are constructed by inserting the heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas...
6869605 BAFF, inhibitors thereof and their use in the modulation of B-cell response  
The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists.
6863890 Treatment of AIDS with antibodies to gamma interferon, alpha interferon and TNF-alpha  
The present disclosure concerns the treatment of a patient with autoimmune disease, including AIDS, by neutralizing, removing or inhibiting different types of interferons, tumor necrosis factor,...
6861510 Immunogenic compositions against gastrin peptides  
Immmunogenic compositions useful for the treatment of ulcers or tumors whose growth is dependent on or stimulated by gastrin hormones are disclosed. The immunogenic compositions induce antibodies...
6861055 Human GDP-mannose 4,6-dehydratase  
The invention provides a novel GDP-mannose 4,6-dehydratase.
6849413 PGRP-L polynucleotides, polypeptides, and antibodies  
The present invention relates to novel human and murine proteins called PGRP-L, and isolated polynucleotides encoding these proteins. Also provided are vectors, host cells, antibodies, and...
6849258 LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation  
The present invention relates to a LO-CD2a antibody and methods of using such antibodies or molecules that bind to the same epitope (or a portion thereof) to prevent and inhibit an immune response...
6843990 Monoclonal antibodies for the detection of decoy receptor 3, hybridomas producing said antibodies and uses thereof  
The invention provides monoclonal antibodies against decoy receptor 3 (DcR3), hybridomas producing said antibodies, kits containing said monoclonal antibodies and uses of the hybridomas, antibodies...
6843989 Methods for the treatment and prevention of cancer using anti-CD40 antibodies  
The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the...
6841152 Methods for protecting against autoimmune diabetes  
Methods are provided for preventing the development of autoimmune diseases in susceptible subjects and for prolonging acceptance of tissue transplants by administration of an agonist of the T cell...
6835380 Antibodies against rat pituitary tumor transforming gene carboxy-terminal (PTTG-C) peptides  
Disclosed are isolated antibodies that specifically bind a rat pituitary tumor transforming gene carboxy-terminal peptide (PTTG-C). These antibodies are believed to be particularly useful in...
6835370 Diagnosis and treatment of malignant neoplasms  
The invention features a method for diagnosing and inhibiting growth of a malignant neoplasm in a mammal by contacting a cell or a bodily fluid of the mammal with an antibody which binds to an...
6833132 Method of stimulating epithelial cells using keratinocyte growth factor (KGF) and method of inhibiting KGF activity  
Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used sucessfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other...
6830751 Use of IL-12 antagonists in the treatment of rheumatoid arthritis  
Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one...
6824779 Methods for inhibiting the interaction of B7-2 with its natural ligand  
The present invention relates to, inter alia, methods for inhibiting the interaction of the B-lymphocyte antigen, B7-2, with its natural ligand on the surface of an immune cell are disclosed. The...
6824993 Antibodies that bind human prostate specific G-protein receptor HPRAJ70  
The present invention relates to PSGR, a novel prostate specific gene with homology to a G-protein coupled receptor overexpressed in prostate cancer. More specifically, the invention relates to...
6821516 Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions  
The invention relates to macrophages which have at least one of the following properties: their cytotoxic activity without IFN-γ is increased by about 20 to 30% with respect to standard...
6822080 Human cyclin-dependent kinase-like proteins and methods of using the same  
Substantially pure human cyclin-dependent kinase-like proteins PITALRE and PISSLRE and isolated protein complexes that comprise PITALRE or PISSLRE are disclosed. Isolated nucleic acid molecule that...
6818213 Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids  
Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor...
6818215 Antibodies to senescent cell-derived inhibiters of DNA synthesis  
Polyclonal and monoclonal antibodies that specifically bind senescent cell derived inhibitor protein (SDI-1), cell lines that produce such monoclonal antibodies, and the use of such antibodies are...
6814965 Methods of decreasing ZVEGF3 activity  
Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that...
6808710 Downmodulating an immune response with multivalent antibodies to PD-1  
The invention identifies PD-1 as a receptor for B7-4. B7-4 can inhibit immune cell activation upon binding to an inhibitory receptor on an immune cell. Accordingly, the invention provides agents...
6803039 Human monoclonal antibody against a costimulatory signal transduction molecule AILIM  
Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal...
6800285 Treatment of central nervous system diseases by antibodies against glatiramer acetate  
The present invention provides humanized polyclonal and humanized monoclonal antibodies directed against an epitope on glatiramer acetate, also known as Copolymer 1, Copolymer-1, Cop-1 or Cop....
6793920 Antithrombotic agent and anti-von willebrand factor monoclonal antibody  
A monoclonal antibody, which has reactivity with human von Willebrand factor, which has action to inhibit RIPA (ristocetin-induced platelet aggregation), BIPA (botrocetin-induced platelet...
6777222 Antibodies to cryptosporidium  
A method of producing IgG1 subclass antibodies reactive to the surface of Crystosporidium oocysts , the method comprising: (a) separating at least a protion of the Cryptosporidium oocyst wall from...
6774219 Candida albicans gene, integrin-like protein, antibodies, and methods of use  
An isolated and purified DNA molecule encoding Candida albicans protein with integrin-like motifs, the protein itself, antibodies thereto, and methods of use, are provided.
6770279 TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis  
A method for treating rheumatoid arthritis using a TNFα antagonist in combination with cyclosporin or analog thereof is disclosed.
6767540 Use of antagonists of plasminogen activator inhibitor-1 (PAI-1) for the treatment of asthma and chronic obstructive pulmonary disease  
The invention relates to methods for treatment of asthma and chronic obstructive pulmonary disease (COPD) by administration of antagonists to plasminogen activator inhibitor type-1 (PAI-1)....
6767541 HER-2/neu overexpression abrogates growth inhibitory pathways  
The present invention provides methods for obtaining genetic profiles of cancer cells in order to assess the status of a cancer in an individual. In addition, the present invention provides methods...
6764679 Antibodies to DcR3 Polypeptide, a TNFR Homolog  
A TNFR homolog, identified as DcR3, is provided. Nucleic acid molecules encoding DcR3, chimeric molecules and antibodies to DcR3 are also provided.
6764681 Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction  
Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in...
6761891 Medicament for treating a manifested lyme disease  
A pharmaceutical composition for treating Lyme disease contains an antibody as an active agent which is specific for the 24 kDa antigen (OspC) of B. burgdorferi , preferably an antibody which is...
6759043 Monoclonal antibodies having property of causing apoptosis  
It is the objective and purpose of the present invention to provide a monoclonal antibody having the property of causing apoptosis on myeloid cells. This invention relates to a monoclonal antibody...
6759519 Antibodies to human G-protein chemokine receptor HDGNR10 (CCR5receptor)  
Antibodies against human G-protein chemokine receptor polypeptides, the polypeptides themselves, DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant...
6759044 Cryptopain antibodies for prophylaxis, treatment, diagnosis and detection of Cryptosporidium species  
Vaccines, antibodies, proteins, DNAs and RNAs for diagnosis, prophylaxis, treatment and detection of Cryptosporidium species or Cryptosporidium species infections. Cryptosporidium species antigen...
6749852 Method for preventing and inhibiting human HLA alloimmune response to platelet transfusion  
The present invention relates to a method for preventing HLA alloimmune response to platelet transfusion. The method comprises the step of presensitizing platelets with at least one monoclonal HLA...
6747133 Antibodies against the tumor suppressor gene ING1  
The invention provides novel tumor suppressor genes, methods for making and using these and related tumor suppressor genes and proteins and peptides, and nucleic acids encoding these and related...
6746673 Pharmaceutical compositions containing anti-Fas antibody  
A pharmaceutical composition containing an anti-human Fas antibody having apoptosis inducing activity and a compound having a folate antagonist activity or a dihydrofolate reductase inhibiting...
6737058 Methods for inhibiting endothelial cell and fibrinogen mediated inflammation using fibrinogen specific antibodies  
The present invention contemplates therapeutic compositions containing a fibrinogen homolog capable of binding to endothelial cells in an RGD-independent manner that inhibits fibrinogen binding to...
6737059 Methods of inhibiting inflammatory processes and alleviating symptoms associated with multiple sclerosis  
Disclosed are methods for the alleviation of symptoms associated with inflammatory disease states, and more particularly to the inhibition of inflammatory disease processes associated with the...
6737511 Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis  
Apoptosis-modifying fusion polypeptides, and the corresponding nucleic acid molecules, are disclosed. Pharmaceutical compositions comprising these polypeptides, and the use of these polypeptides to...